High-dose budesonide for early COVID-19 - Authors' reply.
Saved in:
| Title: | High-dose budesonide for early COVID-19 - Authors' reply. |
|---|---|
| Authors: | Hobbs FDR; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, UK. Electronic address: richard.hobbs@phc.ox.ac.uk., Yu LM; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, UK., Saville BR; Berry Consultants, Austin, TX, USA., Bafadhel M; Nuffield Department of Clinical Medicine, University of Oxford, Oxford OX2 6GG, UK., Butler CC; Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford OX2 6GG, UK. |
| Source: | Lancet (London, England) [Lancet] 2021 Dec 11; Vol. 398 (10317), pp. 2147-2148. |
| Publication Type: | Letter; Comment |
| Journal Info: | Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| ISSN: | 1474-547X |
|---|---|
| DOI: | 10.1016/S0140-6736(21)02449-1 |
